153 related articles for article (PubMed ID: 18801372)
1. The crystal structure of JNK2 reveals conformational flexibility in the MAP kinase insert and indicates its involvement in the regulation of catalytic activity.
Shaw D; Wang SM; Villaseñor AG; Tsing S; Walter D; Browner MF; Barnett J; Kuglstatter A
J Mol Biol; 2008 Nov; 383(4):885-93. PubMed ID: 18801372
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of PTP-SL/PTPBR7 catalytic domain: implications for MAP kinase regulation.
Szedlacsek SE; Aricescu AR; Fulga TA; Renault L; Scheidig AJ
J Mol Biol; 2001 Aug; 311(3):557-68. PubMed ID: 11493009
[TBL] [Abstract][Full Text] [Related]
3. New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding.
Zhang Q; Muller M; Chen CH; Zeng L; Farooq A; Zhou MM
J Mol Biol; 2005 Dec; 354(4):777-88. PubMed ID: 16288922
[TBL] [Abstract][Full Text] [Related]
4. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
5. A novel lipid binding site formed by the MAP kinase insert in p38 alpha.
Diskin R; Engelberg D; Livnah O
J Mol Biol; 2008 Jan; 375(1):70-9. PubMed ID: 17999933
[TBL] [Abstract][Full Text] [Related]
6. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.
Szczepankiewicz BG; Kosogof C; Nelson LT; Liu G; Liu B; Zhao H; Serby MD; Xin Z; Liu M; Gum RJ; Haasch DL; Wang S; Clampit JE; Johnson EF; Lubben TH; Stashko MA; Olejniczak ET; Sun C; Dorwin SA; Haskins K; Abad-Zapatero C; Fry EH; Hutchins CW; Sham HL; Rondinone CM; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3563-80. PubMed ID: 16759099
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Gancz D; Donin N; Fishelson Z
Mol Immunol; 2009 Dec; 47(2-3):310-7. PubMed ID: 19864026
[TBL] [Abstract][Full Text] [Related]
8. Structures of p38alpha active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation.
Diskin R; Lebendiker M; Engelberg D; Livnah O
J Mol Biol; 2007 Jan; 365(1):66-76. PubMed ID: 17059827
[TBL] [Abstract][Full Text] [Related]
9. The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution.
Akella R; Min X; Wu Q; Gardner KH; Goldsmith EJ
Structure; 2010 Dec; 18(12):1571-8. PubMed ID: 21134636
[TBL] [Abstract][Full Text] [Related]
10. A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases.
Pirruccello M; Sondermann H; Pelton JG; Pellicena P; Hoelz A; Chernoff J; Wemmer DE; Kuriyan J
J Mol Biol; 2006 Aug; 361(2):312-26. PubMed ID: 16837009
[TBL] [Abstract][Full Text] [Related]
11. X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.
Kuglstatter A; Ghate M; Tsing S; Villaseñor AG; Shaw D; Barnett JW; Browner MF
Bioorg Med Chem Lett; 2010 Sep; 20(17):5217-20. PubMed ID: 20655210
[TBL] [Abstract][Full Text] [Related]
12. N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3.
Angell RM; Atkinson FL; Brown MJ; Chuang TT; Christopher JA; Cichy-Knight M; Dunn AK; Hightower KE; Malkakorpi S; Musgrave JR; Neu M; Rowland P; Shea RL; Smith JL; Somers DO; Thomas SA; Thompson G; Wang R
Bioorg Med Chem Lett; 2007 Mar; 17(5):1296-301. PubMed ID: 17194588
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of the Mnk2 kinase domain reveal an inhibitory conformation and a zinc binding site.
Jauch R; Jäkel S; Netter C; Schreiter K; Aicher B; Jäckle H; Wahl MC
Structure; 2005 Oct; 13(10):1559-68. PubMed ID: 16216586
[TBL] [Abstract][Full Text] [Related]
14. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
15. The C-terminal domain of Mnk1a plays a dual role in tightly regulating its activity.
Goto S; Yao Z; Proud CG
Biochem J; 2009 Sep; 423(2):279-90. PubMed ID: 19650764
[TBL] [Abstract][Full Text] [Related]
16. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases.
Takekawa M; Tatebayashi K; Saito H
Mol Cell; 2005 Apr; 18(3):295-306. PubMed ID: 15866172
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis.
Kodama Y; Taura K; Miura K; Schnabl B; Osawa Y; Brenner DA
Gastroenterology; 2009 Apr; 136(4):1423-34. PubMed ID: 19249395
[TBL] [Abstract][Full Text] [Related]
18. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia.
Morioka N; Tanabe H; Inoue A; Dohi T; Nakata Y
Neurochem Int; 2009 Sep; 55(4):226-34. PubMed ID: 19524113
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
20. Docking interactions induce exposure of activation loop in the MAP kinase ERK2.
Zhou T; Sun L; Humphreys J; Goldsmith EJ
Structure; 2006 Jun; 14(6):1011-9. PubMed ID: 16765894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
